Vanderbilt Memory and Aging Project: Understanding Brain Aging and Alzheimer's Disease
This observational study, the Vanderbilt Memory and Aging Project, is looking at how your vascular health (blood vessel health) relates to early signs of Alzheimer's disease and other brain changes as you age. Researchers will examine clinical information, brain scans (MRI), and biological markers to understand these connections before significant memory loss occurs. They also want to see how medical and genetic factors, like inflammation or insulin resistance, might play a role. The study aims to enroll 1,000 adults aged 50 and older, with a small group of about 150 participants having mild cognitive impairment. Success will be measured by understanding how vascular health affects brain volume and blood flow over five years.
- Study design
- This is an observational study planning to enroll 1,000 participants aged 50 and older. It does not involve any interventions or treatments.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your brain changes, including white matter hyperintensities, grey matter volume, and cerebral blood flow, will be measured from the start of the study up to five years later.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Vanderbilt Memory and Aging Project
At a glance
Conditions
NCT05372159
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Vanderbilt University Medical Center
Nashville, Tennesseeno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Angela Jefferson, PhD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- White matter hyperintensities Volumebaseline to year five
White matter lesion volume measured by FLAIR imaging modality
- Grey Matter Volumebaseline to year five
Grey matter volume measured by T1 imaging modality
- Cerebral Blood Flowbaseline to year five
Resting cerebral blood flow to brain regions measured by T3 perfusion
- Lacunar infarctsbaseline to year five
Number of lacunar infarcts measured by MRI
- Small vessel microbleedsbaseline to year five
Presence and number of microbleeds measured by MRI
- Left ventricular ejection fractionbaseline to year five
Left ventricular ejection fraction measured by echocardiogram
- Cardiac outputbaseline to year five
Amount of blood the heart pumps from each ventricle per minute, litres per minute (L/min). Measured by echocardiogram
- Cardiac stroke volumebaseline to year five
Stroke volume measured by echocardiogram
- Pulse Wave velocitybaseline to year five
pulse wave velocity measured by cardiac MRI
- Cardiac Strainbaseline to year five
Global longitudinal strain and global circumferential strain measured by cardiac MRI
- Biological marker for Alzheimer's diseasebaseline to year five
Tau, amyloid, neurodegenerative levels measured in cerebrospinal fluid samples
- Blood based biological marker for Alzheimer's diseasebaseline to year five
Tau, amyloid, neurodegenerative levels measured in blood samples
- APOE Genotypebaseline to year five
APOE e4 allele status